Gene amplification as a prognostic factor in primary and secondary high- grade malignant gliomas

Evanthia Galanis, Jan Craig Buckner, D. Kimmel, Robert Brian Jenkins, B. Alderete, J. O'Fallon, C. H. Wang, B. W. Scheithauer, C. D. James

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

The purpose of this study was to examine the incidence of gene amplification in patients with primary (de novo) and secondary high-grade gliomas (gliomas evolving from lower grade malignancies) and to assess its prognostic significance. A total of 186 prospectively collected frozen surgical specimens were analyzed. Extracted DNA was examined by Southern blot using probes corresponding to the EGFR, CDK4, MDM2, N-MYC, CYCD1, PDGFR-α, MET, C-MYC oncogenes. Complete clinical data regarding age, sex, tumor size, extent of surgical resection, postoperative therapy and patient survival were collected. We showed that EGFR followed by CDK4 were the most frequent oncogene amplifications. Oncogene amplification events were significantly more frequent in grade 4 than in grade 3 astrocytomas, mixed gliomas or oligodendrogliomas (P<0.001). With respect to EGFR, there was a significant difference in the frequency of amplification between primary and secondary gliomas (P=0.001); however, no difference in the amplification frequency of the other oncogenes was observed. There was no apparent correlation between the occurrence of gene amplification and patient survival possibly because the genes amplified in human gliomas are part of larger signaling pathways.

Original languageEnglish (US)
Pages (from-to)717-724
Number of pages8
JournalInternational Journal of Oncology
Volume13
Issue number4
StatePublished - 1998

Fingerprint

Gene Amplification
Glioma
Oncogenes
Oligodendroglioma
myc Genes
Survival
Astrocytoma
Southern Blotting
Neoplasms
DNA
Incidence
Genes

Keywords

  • Astrocytomas
  • C-MYC
  • CDK4
  • Cyclin D
  • EGFR
  • GBM
  • Gene amplification
  • Gliomas
  • MDM2
  • MET
  • N- MYC
  • PDGFR-α

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gene amplification as a prognostic factor in primary and secondary high- grade malignant gliomas. / Galanis, Evanthia; Buckner, Jan Craig; Kimmel, D.; Jenkins, Robert Brian; Alderete, B.; O'Fallon, J.; Wang, C. H.; Scheithauer, B. W.; James, C. D.

In: International Journal of Oncology, Vol. 13, No. 4, 1998, p. 717-724.

Research output: Contribution to journalArticle

Galanis, E, Buckner, JC, Kimmel, D, Jenkins, RB, Alderete, B, O'Fallon, J, Wang, CH, Scheithauer, BW & James, CD 1998, 'Gene amplification as a prognostic factor in primary and secondary high- grade malignant gliomas', International Journal of Oncology, vol. 13, no. 4, pp. 717-724.
Galanis, Evanthia ; Buckner, Jan Craig ; Kimmel, D. ; Jenkins, Robert Brian ; Alderete, B. ; O'Fallon, J. ; Wang, C. H. ; Scheithauer, B. W. ; James, C. D. / Gene amplification as a prognostic factor in primary and secondary high- grade malignant gliomas. In: International Journal of Oncology. 1998 ; Vol. 13, No. 4. pp. 717-724.
@article{ae9f0507123c49a7a9328002b7370c7e,
title = "Gene amplification as a prognostic factor in primary and secondary high- grade malignant gliomas",
abstract = "The purpose of this study was to examine the incidence of gene amplification in patients with primary (de novo) and secondary high-grade gliomas (gliomas evolving from lower grade malignancies) and to assess its prognostic significance. A total of 186 prospectively collected frozen surgical specimens were analyzed. Extracted DNA was examined by Southern blot using probes corresponding to the EGFR, CDK4, MDM2, N-MYC, CYCD1, PDGFR-α, MET, C-MYC oncogenes. Complete clinical data regarding age, sex, tumor size, extent of surgical resection, postoperative therapy and patient survival were collected. We showed that EGFR followed by CDK4 were the most frequent oncogene amplifications. Oncogene amplification events were significantly more frequent in grade 4 than in grade 3 astrocytomas, mixed gliomas or oligodendrogliomas (P<0.001). With respect to EGFR, there was a significant difference in the frequency of amplification between primary and secondary gliomas (P=0.001); however, no difference in the amplification frequency of the other oncogenes was observed. There was no apparent correlation between the occurrence of gene amplification and patient survival possibly because the genes amplified in human gliomas are part of larger signaling pathways.",
keywords = "Astrocytomas, C-MYC, CDK4, Cyclin D, EGFR, GBM, Gene amplification, Gliomas, MDM2, MET, N- MYC, PDGFR-α",
author = "Evanthia Galanis and Buckner, {Jan Craig} and D. Kimmel and Jenkins, {Robert Brian} and B. Alderete and J. O'Fallon and Wang, {C. H.} and Scheithauer, {B. W.} and James, {C. D.}",
year = "1998",
language = "English (US)",
volume = "13",
pages = "717--724",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Gene amplification as a prognostic factor in primary and secondary high- grade malignant gliomas

AU - Galanis, Evanthia

AU - Buckner, Jan Craig

AU - Kimmel, D.

AU - Jenkins, Robert Brian

AU - Alderete, B.

AU - O'Fallon, J.

AU - Wang, C. H.

AU - Scheithauer, B. W.

AU - James, C. D.

PY - 1998

Y1 - 1998

N2 - The purpose of this study was to examine the incidence of gene amplification in patients with primary (de novo) and secondary high-grade gliomas (gliomas evolving from lower grade malignancies) and to assess its prognostic significance. A total of 186 prospectively collected frozen surgical specimens were analyzed. Extracted DNA was examined by Southern blot using probes corresponding to the EGFR, CDK4, MDM2, N-MYC, CYCD1, PDGFR-α, MET, C-MYC oncogenes. Complete clinical data regarding age, sex, tumor size, extent of surgical resection, postoperative therapy and patient survival were collected. We showed that EGFR followed by CDK4 were the most frequent oncogene amplifications. Oncogene amplification events were significantly more frequent in grade 4 than in grade 3 astrocytomas, mixed gliomas or oligodendrogliomas (P<0.001). With respect to EGFR, there was a significant difference in the frequency of amplification between primary and secondary gliomas (P=0.001); however, no difference in the amplification frequency of the other oncogenes was observed. There was no apparent correlation between the occurrence of gene amplification and patient survival possibly because the genes amplified in human gliomas are part of larger signaling pathways.

AB - The purpose of this study was to examine the incidence of gene amplification in patients with primary (de novo) and secondary high-grade gliomas (gliomas evolving from lower grade malignancies) and to assess its prognostic significance. A total of 186 prospectively collected frozen surgical specimens were analyzed. Extracted DNA was examined by Southern blot using probes corresponding to the EGFR, CDK4, MDM2, N-MYC, CYCD1, PDGFR-α, MET, C-MYC oncogenes. Complete clinical data regarding age, sex, tumor size, extent of surgical resection, postoperative therapy and patient survival were collected. We showed that EGFR followed by CDK4 were the most frequent oncogene amplifications. Oncogene amplification events were significantly more frequent in grade 4 than in grade 3 astrocytomas, mixed gliomas or oligodendrogliomas (P<0.001). With respect to EGFR, there was a significant difference in the frequency of amplification between primary and secondary gliomas (P=0.001); however, no difference in the amplification frequency of the other oncogenes was observed. There was no apparent correlation between the occurrence of gene amplification and patient survival possibly because the genes amplified in human gliomas are part of larger signaling pathways.

KW - Astrocytomas

KW - C-MYC

KW - CDK4

KW - Cyclin D

KW - EGFR

KW - GBM

KW - Gene amplification

KW - Gliomas

KW - MDM2

KW - MET

KW - N- MYC

KW - PDGFR-α

UR - http://www.scopus.com/inward/record.url?scp=0031671411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031671411&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 717

EP - 724

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 4

ER -